This site is intended for healthcare professionals
News

Health Canada approves Sunosi for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Jazz Pharma

Read time: 1 mins
Published:1st Sep 2021
Jazz Pharmaceuticals plc announced the Health Canada approval and availability of Sunosi (solriamfetol) for the treatment of excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA) in adult patients. Once-daily?Sunosi?is approved with doses of 75 mg and 150 mg. Sunosi?is the first dopamine and norepinephrine reuptake inhibitor (DNRI) approved to treat EDS in adults living with narcolepsy or OSA. EDS?is characterized by the inability to stay awake and alert during the day resulting in unplanned lapses into sleep or drowsiness.

Major contributors to EDS are narcolepsy, a chronic, debilitating neurological disorder characterized by the inability to regulate sleep-wake cycles normally and OSA, a condition where a person's breathing stops for brief periods of time when they sleep.

Condition: Sleeping Disorders/Narcolepsy
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.